sarilumab - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.91 [0.61, 1.35]< 111%5 studies (5/-)68.3 %highnot evaluable lowcrucial-
clinical improvement 1.43 [1.01, 2.04]> 146%4 studies (4/-)97.8 %highnot evaluable lowimportant-
clinical improvement (14-day) 1.86 [1.20, 2.87]> 10%1 study (1/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.87, 1.35]> 10%2 studies (2/-)76.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.53 [0.30, 0.94]< 120%2 studies (2/-)98.5 %highnot evaluable lowimportant-
mechanical ventilation 0.27 [0.14, 0.55]< 10%2 studies (2/-)100.0 %highnot evaluable lowimportant-
off oxygenation 1.46 [0.79, 2.68]> 128%2 studies (2/-)88.7 %highnot evaluable lownon important-

safety endpoints 00

serious adverse events 1.26 [0.82, 1.94]< 10%2 studies (2/-)14.4 %some concernnot evaluable moderateimportant-
adverse events 1.13 [0.77, 1.67]< 10%2 studies (2/-)26.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.